Caida Securities is a provider of securities brokerage and financial consulting services.
Caida Securities, founded in April 2002 and headquartered in Hebei, is a financial services company. Listed on the Shanghai Stock Exchange on May 7, 2021, the company’s major shareholders are Tanggang Group and the State-owned Assets Supervision and Administration Commission of Hebei Province. Rivals that have direct and indirect competition with Caida Securities include Shenwan Hongyuan Securities Co., Ltd., Guotai Junan Securities Co.,Ltd. and Hna Group Co., Ltd..
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
“I entered the venture capital industry in 2008. I experienced the financial crisis in 2009 and the boom of the classical venture capital model from 2011 to 2015. Having experienced many ups and downs, I believe that venture capital will tide over the tough period and usher in new opportunities.”
May 12, 2022 05:41 PM
Electrophysiology AccuPulse Raises Nearly CNY 100 Million in Series A Funding
Founded in November 2020, Suzhou AccuPulse is committed to becoming an international leading platform-based innovative cardiac electrophysiology company. The company has established a research and development team led by well-known electrophysiological experts in the US with R&D centers in Suzhou and in the United States.
May 20, 2022 05:17 PM
IDG Backed Weimu Medical Raises CNY Tens of Millions Series Pre-A Funding Round
Founded in 2020, Shanghai Weimu Medical has built a high-end interventional medical device platform that is based on innovative materials in the fields of tumor intervention and pan-vascular intervention. The company has developed a number of products such as microspheres hydrogels and tissue adhesives.
May 19, 2022 07:13 PM
Cell Therapy Developer Senlang Bio Raises CNY 200 Million in New Funding Round
Founded in 2016, Hebei Senlang Bio is a clinical-stage biotechnology company dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers.
May 18, 2022 01:00 PM